Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PHAT
PHAT logo

PHAT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Phathom Pharmaceuticals Inc (PHAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.380
1 Day change
1.61%
52 Week Range
18.310
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PHAT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows improving short-term momentum and bullish options sentiment, but the lack of recent news, no strong proprietary buy signal, neutral insider/hedge fund activity, and no usable latest-quarter financial snapshot make this more of a watchlist name than a conviction long-term entry. Based on the available data, I would not call it a clear buy today.

Technical Analysis

The chart is mildly constructive. MACD histogram is positive and expanding, which supports short-term upside momentum. RSI at 65.3 is near the upper end of neutral and does not yet signal an overbought condition. Moving averages are converging, suggesting the stock may be at an inflection point rather than in a confirmed strong trend. Price is sitting close to pivot resistance at 11.252, with immediate support at 10.725 and deeper support at 10.198. Since the market closed at 10.97, PHAT is trading above the pivot but below resistance, implying a modestly bullish but not decisive setup.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is very bullish on open interest, with a very low put-call ratio of 0.07, indicating heavy call positioning versus puts. However, the option volume put-call ratio of 1.65 suggests more put activity in the current session than call activity, which tempers the bullish read a bit. Implied volatility is elevated at 138.75, and volume today is above the 30-day average, so options are active and the market is expecting meaningful movement. Overall, options data leans bullish but not cleanly enough to override the lack of a strong trading signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
6

Positive Catalysts

  • ["MACD histogram is positive and expanding, showing improving momentum.", "Options open interest is strongly call-skewed, suggesting bullish sentiment.", "Stock trend model suggests positive near-term upside over 1 week and 1 month.", "Price is trading above the pivot level, which supports a constructive short-term setup."]

Neutral/Negative Catalysts

  • ["No recent news in the past week, so there is no clear event-driven catalyst.", "No AI Stock Picker signal today.", "No recent SwingMax buy signal.", "Hedge funds and insiders are both neutral, with no notable accumulation trends.", "RSI is elevated near the upper neutral range, so upside is not deeply discounted.", "No recent congress trading data available."]

Financial Performance

No latest-quarter financial snapshot was available because the provided financial data returned an error, so I cannot verify recent revenue, earnings, or margin growth. The latest quarter season could not be identified from the available data. Because of that, there is no solid fundamental confirmation for a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence here of recent Wall Street upgrades, downgrades, or target changes. Based on the broader picture, Wall Street sentiment cannot be confirmed as strongly bullish or bearish from the available dataset. Pros: improving technical momentum and supportive options positioning. Cons: no clear catalyst, no proprietary buy signal, no visible insider/hedge fund accumulation, and no fundamental/analyst confirmation.

Wall Street analysts forecast PHAT stock price to rise
6 Analyst Rating
Wall Street analysts forecast PHAT stock price to rise
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.200
sliders
Low
16
Averages
25.4
High
29
Current: 11.200
sliders
Low
16
Averages
25.4
High
29
Barclays
Jenna Davidner
Equal Weight -> Overweight
upgrade
$16 -> $18
AI Analysis
2026-03-27
Reason
Barclays
Jenna Davidner
Price Target
$16 -> $18
AI Analysis
2026-03-27
upgrade
Equal Weight -> Overweight
Reason
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals to Overweight from Equal Weight with a price target of $18, up from $16. The company's Q1 trends are "lighter," but the shares offer an attractive entry point ahead of the expected volume and revenue ramp for the remainder of the year, the analyst tells investors in a research note. The firm believes weekly prescriptions data could be a positive catalyst for Phathom shares. The stock's setup is positive with consensus revenue expectations at the midpoint of the company's guidance, contends Barclays.
Guggenheim
Buy
maintain
$20 -> $25
2026-02-27
Reason
Guggenheim
Price Target
$20 -> $25
2026-02-27
maintain
Buy
Reason
Guggenheim raised the firm's price target on Phathom Pharmaceuticals to $25 from $20 and keeps a Buy rating on the shares. The firm, which continues to be "encouraged" by the company's goal to achieve profitability in early Q3 of 2026, updated its model to reflect Q4 financials.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PHAT
Unlock Now

People Also Watch